Preclinical evidence in support of repurposing sub-anesthetic ketamine as a treatment for L-DOPA-induced dyskinesia

Parkinson’s disease (PD) is the second most common neurodegenerative disease. Pharmacotherapy with L-DOPA remains the gold-standard therapy for PD, but is often limited by the development of the common side effect of L-DOPA-induced dyskinesia (LID), which can become debilitating. The only effective...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Exp Neurol
Main Authors: Bartlett, Mitchell J., Flores, Andrew J., Ye, Tony, Smidt, Saskia I., Dollish, Hannah K., Stancati, Jennifer A., Farrell, Drew C., Parent, Kate L., Doyle, Kristian P., Besselsen, David G., Heien, Michael L., Cowen, Stephen L., Steece-Collier, Kathy, Sherman, Scott J., Falk, Torsten
Formato: Artigo
Idioma:Inglês
Publicado: 2020
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7518549/
https://ncbi.nlm.nih.gov/pubmed/32717354
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.expneurol.2020.113413
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares